Navigation Links
BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
Date:12/9/2011

hat XIAFLEX is approved for Dupuytren's contracture in the United States and Europe and is moving forward with multiple clinical trials for additional indications, BioSpecifics has major progress potential ahead and I look forward to contributing to its continued success," said Mr. Gould.

"We are delighted that George has joined our Board of Directors. He has sat on the board of a number of public pharmaceutical companies and was at Hoffmann-La Roche for 28 years as a Vice President in licensing and IP. I believe his experience and expertise will be invaluable to BioSpecifics as XIAFLEX advances toward approval in several new clinical indications," reflected Thomas Wegman, President of BioSpecifics.

Mr. Gould has served on the Board of Directors of Tapestry Pharmaceuticals, Supratek Pharma, AngioGenex and Protein Design Labs. Prior to his current work, he was Senior Vice President at Pharmagenics for 1 year and before that, he was Vice President of Licensing and Corporate Development and Chief Patent Counsel at Hoffmann-La Roche for 28 years. He was also a Senior Patent Attorney at Esso Research & Engineering Co. for 6 years and was an organic chemist at Merck. He holds a JD from Columbia University School of Law and a LLM from New York University School of Law. He received a BA in Organic Chemistry from The Johns Hopkins University.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says ... been known to react more aggressively when hormones change, and ... puberty, other acne causing factors like P.acnes bacteria and excess ... with unsightly acne scars. Adult acne treatment, Probiotic Action shares ... how to reduce and prevent acne scarring. , In order ...
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... Celsion Corporation (Nasdaq: CLSN ), an oncology ... of innovative oncology drugs, today announced that it has ... select group of institutional investors, including certain officers and ... 8% redeemable convertible preferred stock with a stated value ...
... massive death of brain cells after a stroke, the explosion in ... as autism, schizophrenia and mental retardation show no physical signs of ... brain cells communicate with one another. To understand ... activity is key. But even the best imaging devices available ...
... success of the previous conferences of the series held ... (EPD) conferences are a leading venue for experts from ... as a processing technique for fabrication of both traditional ... electric surface charge on particles in suspension, which migrate ...
Cached Biology Technology:Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4New UCLA-designed microscope records firing of thousands of individual neurons in 3-D 2New UCLA-designed microscope records firing of thousands of individual neurons in 3-D 34th International Conference on Electrophoretic Deposition 24th International Conference on Electrophoretic Deposition 34th International Conference on Electrophoretic Deposition 4
(Date:5/17/2013)... of proteins in the brain responsible for protecting nerve ... could increase cell survival. , The discovery, made by ... in the EMBO journal with additional comment ... for stroke and other brain diseases. , The research ... a protein, known as SUMO, responsible for controlling the ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society for Developmental Biology (SDB) 72nd Annual Meeting ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the SDB 2013 Annual Meeting. , Awards are ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... China - A group of scientists from United Kingdom (UK), ... sequencing of peregrine and saker falcons genomes at the 2nd ... study is a part of Falcon Genome Project, launched and ... this January. The results will enable biologists to better study ...
... BioInnovation Institute in Akron (ABIA) and the U.S. Food ... collaboration to support and develop regulatory science for the ... Effective today, the FDA and ABIA executed a ... draw upon ABIA resourcesincluding a library of test methods ...
... -- Believed critical for determining which individuals can -- or ... figure prominently in the origin of new species, but are ... new species form. Today, new international research led ... the exact shape and fit of genitalia steals the show ...
Cached Biology News:Genomic sequences of 2 iconic falconry birds - Peregrine and Saker Falcons- successfully decoded 2FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2Shape, fit of reproductive organs evolve quickly and in concert, leaving size behind 2Shape, fit of reproductive organs evolve quickly and in concert, leaving size behind 3
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
...
Biology Products: